Alector Q4 2021 net loss $55.6M; cash $735M plus $200M from GSK; pipeline advancing

Alector, Inc.

2022-FY EPS reported -$0.45 revenue$207,085,000

Net loss Q4 2021 $55.6M ($0.68/share) vs $52.2M ($0.66) in Q4 2020; full-year net loss $36.3M ($0.45) vs $190.2M ($2.45).
Collaboration revenue Q4 $14.0M (up from $4.9M); full-year $207.1M (up from $21.1M) driven by GSK deal.
Cash $735.3M at Dec 31, 2021; plus $200M from GSK in Jan 2022. Cash runway expected into mid-2024.
AL002 Phase 2 ARIA observed; protocol amended to exclude APOE e4/e4 homozygotes.
Appointed Sara Kenkare-Mitra (President/Head R&D) and Marc Grasso (CFO).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.